Oncotelic Therapeutics Files First Quarter 2026 Financial Results and Strategic Progress

Agoura Hills, Calif., May 15, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) (“Oncotelic” or the “Company”), a clinical-stage biotechnology company focused on oncology, AI-enabled drug development, and advanced drug delivery platforms, yesterday filed financial results for the quarter ended March 31, 2026 through its Quarterly Report on Form 10-Q, and is providing a corporate update highlighting progress across its therapeutic and platform initiatives.